Lap Chole Within 48 Hours Optimal in Acute Cholecystitis

This article originally appeared here.
Share this content:
Lap Chole Within 48 Hours Optimal in Acute Cholecystitis
Lap Chole Within 48 Hours Optimal in Acute Cholecystitis

THURSDAY, Dec. 18, 2014 (HealthDay News) -- The first 48 hours appears to be the optimal time for performing early laparoscopic cholecystectomy (LC) for acute cholecystitis, according to research published online Dec. 17 in JAMA Surgery.

Syed Nabeel Zafar, M.B.B.S., M.P.H., of the Howard University Hospital in Washington, D.C., and colleagues retrospectively reviewed prospectively collected data for 95,523 adults, aged 18 years and older, who underwent LC within 10 days of presentation for acute cholecystitis. Clinical outcomes and costs were examined according to length of time from presentation to surgery.

The researchers found that, compared with patients undergoing LC on days zero through one, those undergoing LC on days two through five, and particularly those undergoing LC on days six through 10, may have higher risk of mortality (odds ratios [ORs], 1.26 [95 percent confidence interval (CI), 1.00 to 1.58] and 1.93 [95 percent CI, 1.38 to 2.68], respectively) and postoperative infection (ORs, 0.88 [95 percent CI, 0.69 to 1.12] and 1.53 [95 percent CI, 1.05 to 2.23], respectively). Adjusted mean hospital cost was higher for those who had surgery on days six through 10 ($17,745) than for those who had surgery on days zero through one ($8,974).

"Laparoscopic cholecystectomy performed within two days of presentation of acute cholecystitis yielded the best outcomes and lowest costs," the authors write. "Although causality could not be established, delaying LC was associated with more complications, higher mortality, and higher costs."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »